RELATED REPORTS
Tags: blood cancerbortezomibcancerdexamethasonehematologylenalidomidelong term survival outcomesmedian progression free survivalmelflufenmelphalan flufenamidemulticentremultiple myelomaneutropeniaoncologyopen labelopen label trialoverall survivalprogression-free survivalrelapsed and refractory multiple myelomaRRMMsafetysurvival outcomesthrombocytopenia






![Type I diabetes not associated with early menopause [OVADIA study]](https://www.2minutemedicine.com/wp-content/uploads/2014/12/diabetes1_edited-75x75.jpg)
